At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 187 enrolled
Drug / intervention
bevacizumab +2 moredrug
Likely dose
bevacizumab 5 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase 2 Study Of The Anti-Angiogenesis Agent AG-013736 In Combinations With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer Preceded By A Phase 1 Portion
In Brief
A Phase 2 clinical trial evaluating bevacizumab, AG-013726, and 1 other intervention for Colorectal Neoplasms. Completed, enrolled 187 participants across 106 sites.
Detailed Summary
To determine the safety and efficacy of AG-013736 in combination with other standard of care medication in patients with first line metastatic colorectal cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Neoplasms
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2006
First PostedApr 2007
Primary CompletionApr 2012
Study CompletionNov 2012
TodayJul 2026
First PostedApr 16, 2007
Enrollment StartJan 1, 2006
Primary CompletionApr 1, 2012
Study CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 19.2 years ago
Interventions
bevacizumabdrug
bevacizumab 5 mg/kg every 2 weeks
AG-013726drug
AG-013726 5 mg bid every 2 weeks
AG-013736 (axitinib)drug
AG-013736 5 mg bid starting dose